Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.

ABSTRACT:

Objective

To find the combination of candidate biomarkers and cognitive endpoints to maximize statistical power and minimize cost of clinical trials of healthy elders at risk for cognitive decline due to Alzheimer's disease.

Methods

Four-hundred and twelve cognitively normal participants were followed over 7 years. Nonlinear methods were used to estimate the longitudinal trajectories of several cognitive outcomes including delayed memory recall, executive function, processing speed, and several cognitive composites by subgroups selected on the basis of biomarkers, including APOE-ε4 allele carriers, cerebrospinal fluid biomarkers (Aβ 42, total tau, and phosphorylated tau), and those with small hippocampi.

Results

Derived cognitive composites combining Alzheimer's Disea

SUBMITTER: Insel PS 

PROVIDER: S-EPMC4435707 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature